Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Cytoreductive Surgery (CRS) and Hyperthermic Intraoperative Peritoneal Chemotherapy (HIPEC) form a combined innovative treatment, applied for Peritoneal Surface Malignancies (PSM).
What is CRS (Cytoreductive Surgery)
Cytoreductive Surgery resulted from modern surgery’s progress and advances in surgical techniques and aims to the excision of all visible tumors from the abdominal cavity.
Through CRS technique, skilled CRS surgeon removes all visible tumors from the abdomen and in some cases, if deemed necessary, surgeon may proceed to the partial or complete removal of affected organs.
What is HIPEC (Hyperthermic Intraoperative Peritoneal Chemotherapy)
Hyperthermic intraoperative peritoneal chemotherapy takes aim at all invisible cancer cells and neoplastic deposits into the abdominal cavity.
It is an innovative procedure with the help of which chemotherapy solution, heated to 42-43C, is delivered into the abdomen for 90 minutes.
Tumors located in the abdominal cavity and especially those found in the surface of organs and the abdominal wall are very difficult to be treated by standard intravenous chemotherapeutic agents.
In such cases HIPEC is indicated as a treatment of choice.
In addition to this and due to its low rate of systematic absorption, higher dose of chemotherapeutic agents can be used without the systemic side effects of intravenous chemotherapy.
Who is a candidate for CRS + HIPEC
Patients with cancers that primarily emerged or spread to the abdominal cavity.
-Colon and Rectal cancer
-Gastric and Stomach cancer
-Desmoplastic small round cell tumors
-Primary Peritoneal or Primary Abdominal cancer
CRS + HIPEC is a procedure that strongly requires rigorous patient’s assessment, thorough preoperative evaluation and a high experienced multidisciplinary team in order to achieve the desired outcome with the utmost safety and efficiency.